NASDAQ: PEARPear Therapeutics Inc Stock
$0.39-0.20 (-33.9%)
Updated Mar 17, 2023
PEAR Price
$0.39
Fair Value Price
$0.99
Market Cap
$54.42M
52 Week Low
$0.30
52 Week High
$6.74
P/E
0.06x
P/B
1.04x
P/S
24.76x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.45M
Earnings
-$30.37M
Gross Margin
29.4%
Operating Margin
-238.5%
Profit Margin
-265.3%
Debt to Equity
1.29
Operating Cash Flow
-$129M
Beta
1.18
Next Earnings
Mar 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A
PEAR Overview
Pear Therapeutics, Inc. develops and sells software-based medicines (reSET, a treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants, reSET-O, a treatment of opioid use disorder in combination with buprenorphine, and Somryst, a software-based treatment for chronic insomnia). It is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and gastrointestinal, oncological, and cardiovascular diseases. Pear Therapeutics was incorporated in 2013 and is headquarteredin Boston, MA.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PEAR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PEAR ($0.39) is undervalued by 60.77% relative to our estimate of its Fair Value price of $0.99 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PEAR ($0.39) is significantly undervalued by 60.77% relative to our estimate of its Fair Value price of $0.99 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PEAR is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PEAR due diligence checks available for Premium users.
Be the first to know about important PEAR news, forecast changes, insider trades & much more!
PEAR News
Valuation
PEAR fair value
Fair Value of PEAR stock based on Discounted Cash Flow (DCF)
Price
$0.39
Fair Value
$0.99
Undervalued by
60.77%
PEAR ($0.39) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PEAR ($0.39) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PEAR is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PEAR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.06x
Industry
3.11x
Market
21.81x
PEAR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PEAR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PEAR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.04x
Industry
3.41x
PEAR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PEAR's financial health
Profit margin
Revenue
$4.1M
Net Income
-$30.7M
Profit Margin
-752.5%
PEAR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PEAR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$119.7M
Liabilities
$67.5M
Debt to equity
1.29
PEAR's short-term assets ($98.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PEAR's short-term assets ($98.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PEAR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.3M
Investing
$22.4M
Financing
$358.0k
PEAR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PEAR vs Health Information Service Stocks
Pear Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.